Targets › FIG4
1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Dec 2032.
Dual specificity phosphatase component of the PI(3,5)P2 regulatory complex which regulates both the synthesis and turnover of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2). Catalyzes the dephosphorylation of phosphatidylinositol 3,5-bisphosphate (PtdIns(3,5)P2) to form phosphatidylinositol 3-phosphate. (UniProt, Q92562)
Open in Phaseline: the race on FIG4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Elpida Therapeutics SPC | ELP-02 AAV9-based gene therapy expressing FIG4 | FIG4 | Phase 1 | Charcot-Marie-Tooth Disease Type 4J | Dec 2032 |
Charcot-Marie-Tooth Disease Type 4J (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.